May 2016 Vol 9, No 3
Automated dispensing cabinets (ADCs) have helped in monitoring quality-assurance data, particularly related to dispensation and diversion of controlled substances. This article describes the characteristics of controlled substance discrepancies found at a Level I trauma hospital among Medicare patients and the use of an ADC at the medical facility.
Dramatic Increase in Misuse of Controlled Substances a Concern for All Stakeholders
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation
Chronic obstructive pulmonary disease (COPD) is characterized by persistent, progressive airflow limitation that is not fully reversible. This study analyzed the effects of early versus delayed initiation of roflumilast treatment after a hospital or emergency department discharge resulting from COPD exacerbation.
Continuing Challenges in COPD Management, Despite Its Prevalence and High Economic Burden
Increased Burden of Healthcare Utilization and Cost Associated with Opioid-Related Constipation Among Patients with Noncancer Pain
Ancilla W. Fernandes, PhD, David M. Kern, PhD, Catherine Datto, MD, MS, Yen-Wen Chen, PhD, Charles McLeskey, MD, Ozgur Tunceli, PhD
Opioid-induced constipation can adversely affect patients’ quality of life. This study was designed to assess healthcare utilization and costs, including all-cause, constipation-related, and pain-related costs, for patients with versus those without opioid-induced constipation.
Can Improved Management of Opioid-Induced Constipation Mitigate the Associated Costs?
Here are summaries of some studies presented at this year's Annual Meeting of the Academy of Managed Care Pharmacy. These studies highlight some of the main trends in healthcare with important implications for payers, employers, drug manufacturers, providers, patients, and other healthcare stakeholders.
In 2014, the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C raised concerns among the employer community in the United States. The cost implications of these specialty drugs, based on the possibility of their widespread use in patients without advanced disease, had corporate executives hurriedly recalculating their healthcare budgets.
Results 1 - 6 of 6